TY - JOUR
T1 - Baseline differences in the HF-ACTION trial by sex
AU - Piña, Ileana L.
AU - Kokkinos, Peter
AU - Kao, Andrew
AU - Bittner, Vera
AU - Saval, Matt
AU - Clare, Bob
AU - Goldberg, Lee
AU - Johnson, Maryl
AU - Swank, Ann
AU - Ventura, Hector
AU - Moe, Gordon
AU - Fitz-Gerald, Meredith
AU - Ellis, Stephen J.
AU - Vest, Marianne
AU - Cooper, Lawton
AU - Whellan, David
N1 - Funding Information:
A complete list of the HF-ACTION investigators is available as an appendix in the introduction of this supplement. This research was supported by grants from the National Institutes of Health: 5U01HL063747, 5U01HL068973, 5U01HL066501, 5U01HL066482, 5U01HL064250, 5U01HL066494, 5U01HL064257, 5U01HL066497, 5U01HL068980, 5U01HL064265, 5U01HL066491, 5U01HL064264, 5U01HL066461, R37AG18915, and P60AG10484.
Funding Information:
I. Piña has received a research grant from NIH, is consultant for FDA, and Sanofi-Aventis, and has served on speaking bureaus for AZ, Merck, Solvay, and Novartis. L. Goldberg has served on a speaking bureau for GSK, and on an advisory board for Alere Medical. M. Johnson is a consultant for CVS and is a XDX-IMAGE trial DSMB member and is a part of the Transmedic-clinical events committee for clincal trial. P. Kikkinos, A. Kao, V. Bittner, M. Saval, R. Clare, A. Swank, G. Moe, M. Fitz-Gerald, S. Ellis, M. Vest, L. Cooper, and D. Whellan have no conflicts of interest to disclose.
PY - 2009/10
Y1 - 2009/10
N2 - Background: In patients with heart failure (HF), assessment of functional capacity plays an important prognostic role. Both 6-minute walk and cardiopulmonary exercise testing have been used to determine physical function and to determine prognosis and even listing for transplantation. However, as in HF trials, the number of women reported has been small, and the cutoffs for transplantation have been representative of male populations and extrapolated to women. It is also well known that peak VO2 as a determinant of fitness is inherently lower in women than in men and potentially much lower in the presence of HF. Values for a female population from which to draw for this important determination are lacking. Methods: The HF-ACTION trial randomized 2,331 patients (28% women) with New York Heart Association class II-IV HF due to systolic dysfunction to either a formal exercise program in addition to optimal medical therapy or to optimal medical therapy alone without any formal exercise training. To characterize differences between men and women in the interpretation of final cardiopulmonary exercise testing models, the interaction of individual covariates with sex was investigated in the models of (1) VE/VCO2, (2) VO2 at ventilatory threshold (VT), (3) distance on the 6-minute walk, and (4) peak VO2. Results: The women were younger than the men and more likely to have a nonischemic etiology and a higher ejection fraction. Dose of angiotensin converting enzyme inhibitor (ACEI) was lower in the women, on average. The lower ACEI dose may reflect the higher use of angiotensin II receptor blocker (ARB) in women. Both the peak VO2 and the 6-minute walk distance were significantly lower in the women than in the men. Perhaps the most significant finding in this dataset of baseline characteristics is that the peak VO2 for women was significantly lower than that for men with similar ventricular function and health status. Conclusion: Therefore, in a well-medicated, stable, class II-IV HF cohort of patients who are able to exercise, women have statistically significantly lower peak VO2 and 6-minute walk distance than men with similar health status and ventricular function. These data should prompt careful thought when considering prognostic markers for women and listing for cardiac transplant.
AB - Background: In patients with heart failure (HF), assessment of functional capacity plays an important prognostic role. Both 6-minute walk and cardiopulmonary exercise testing have been used to determine physical function and to determine prognosis and even listing for transplantation. However, as in HF trials, the number of women reported has been small, and the cutoffs for transplantation have been representative of male populations and extrapolated to women. It is also well known that peak VO2 as a determinant of fitness is inherently lower in women than in men and potentially much lower in the presence of HF. Values for a female population from which to draw for this important determination are lacking. Methods: The HF-ACTION trial randomized 2,331 patients (28% women) with New York Heart Association class II-IV HF due to systolic dysfunction to either a formal exercise program in addition to optimal medical therapy or to optimal medical therapy alone without any formal exercise training. To characterize differences between men and women in the interpretation of final cardiopulmonary exercise testing models, the interaction of individual covariates with sex was investigated in the models of (1) VE/VCO2, (2) VO2 at ventilatory threshold (VT), (3) distance on the 6-minute walk, and (4) peak VO2. Results: The women were younger than the men and more likely to have a nonischemic etiology and a higher ejection fraction. Dose of angiotensin converting enzyme inhibitor (ACEI) was lower in the women, on average. The lower ACEI dose may reflect the higher use of angiotensin II receptor blocker (ARB) in women. Both the peak VO2 and the 6-minute walk distance were significantly lower in the women than in the men. Perhaps the most significant finding in this dataset of baseline characteristics is that the peak VO2 for women was significantly lower than that for men with similar ventricular function and health status. Conclusion: Therefore, in a well-medicated, stable, class II-IV HF cohort of patients who are able to exercise, women have statistically significantly lower peak VO2 and 6-minute walk distance than men with similar health status and ventricular function. These data should prompt careful thought when considering prognostic markers for women and listing for cardiac transplant.
UR - http://www.scopus.com/inward/record.url?scp=70349410452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349410452&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2009.07.012
DO - 10.1016/j.ahj.2009.07.012
M3 - Article
C2 - 19782784
AN - SCOPUS:70349410452
SN - 0002-8703
VL - 158
SP - S16-S23
JO - American Heart Journal
JF - American Heart Journal
IS - 4 SUPPL.
ER -